Information

Nuage Therapeutics’ aim is to change the paradigm of Intrinsically Disordered Proteins (IDPs), considered "undruggable" (pharmacologically unapproachable) until now. Nuage Tx discovery engine for small molecule modulators of disordered proteins turns IDPs into "druggable" (pharmacologically approachable) using, in a unique way in the industry, cutting-edge knowledge developed by our scientific founders. Our mission is to develop potent and selective therapeutic compounds addressing diseases with a clear unmet medical need to improve patient’s lives.
Nuage Tx is a spin-off of IRB and ICREA, founded in 2021, based in Barcelona.